MSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the ...

MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated diffuse large B-cell lymphoma (DLBCL), cementing the antibody-drug conjugate's ...

Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying ...

Co., Inc. (NYSE:MRK), recently acquired 15,000 shares of the company's common stock. The transaction, which took place on ...

Co., Inc. (NYSE:MRK), recently purchased 2,832.861 shares of the company's common stock. The acquisition, valued at approximately $249,999, was completed at a price of $88.25 per share. Following this ...

CAR T-Cell therapy market growth is propelled by revolutionary results in treating certain blood cancers.New Delhi, Feb. 07, 2025 (GLOBE NEWSWIRE) -- The global CAR T-cell therapy market valuation is ...

Genentech has shared positive data from the Phase III REGENCY trial with regulators in the US and EU. Roche’s subsidiary ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued ...

Caribou Biosciences (NASDAQ:CRBU – Get Free Report) and Atyr PHARMA (NASDAQ:ATYR – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two ...

Adicet Bio (NASDAQ:ACET – Get Free Report)‘s stock had its “neutral” rating reissued by investment analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. A number of other ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published ...